Lundbeck drug candidate shows promise in Cushing's disease trial

H. Lundbeck said its investigational drug asedebart showed encouraging tolerability and efficacy signals in a small mid-stage study for Cushing's disease. The update is a positive clinical-development step for the company, but the data are early-stage and from a limited patient sample. Market impact should be modest unless follow-up trials show stronger efficacy and safety.

Analysis

H. Lundbeck said its investigational drug asedebart showed encouraging tolerability and efficacy signals in a small mid-stage study for Cushing's disease. The update is a positive clinical-development step for the company, but the data are early-stage and from a limited patient sample. Market impact should be modest unless follow-up trials show stronger efficacy and safety.